Voyager Therapeutics, Inc.

Case Overview
Status: | Status: Investigating |
Company Name: | Company Name: Voyager Therapeutics, Inc. |
Ticker: | Ticker: VYGR |
Related Attorneys: | Lead Attorneys: Thomas W. Elrod |
Related Practices: | Related Practices: Securities |
The law firm of Kirby McInerney LLP is investigating potential claims against Voyager Therapeutics, Inc. (“Voyager” or the “Company”) (NASDAQ:VYGR). The investigation concerns whether Voyager and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices.
On February 11, 2025, Voyager issued a press release “announc[ing] it has decided to assess alternate payloads related to its gene therapy program for superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS)”, stating that “[e]merging preclinical data indicate the siRNA payload component of VY9323 does not meet our high standards due to what appears to be an off-target effect resulting a narrowed therapeutic window.” Voyager further stated that it “no longer anticipates filing an investigational new drug (IND) application for VY9323 in mid-2025.” On this news, the price of Voyager shares declined by $1.11 per share, or approximately 20%, from $5.32 per share on February 10, 2025, to close at $4.41 on February 11, 2025.
On February 11, 2025, Voyager issued a press release “announc[ing] it has decided to assess alternate payloads related to its gene therapy program for superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS)”, stating that “[e]merging preclinical data indicate the siRNA payload component of VY9323 does not meet our high standards due to what appears to be an off-target effect resulting a narrowed therapeutic window.” Voyager further stated that it “no longer anticipates filing an investigational new drug (IND) application for VY9323 in mid-2025.” On this news, the price of Voyager shares declined by $1.11 per share, or approximately 20%, from $5.32 per share on February 10, 2025, to close at $4.41 on February 11, 2025.